CN103919824A - Lipid-lowering plant extract and application of the lipid-lowering plant extract in preparation of medicine or health care products - Google Patents
Lipid-lowering plant extract and application of the lipid-lowering plant extract in preparation of medicine or health care products Download PDFInfo
- Publication number
- CN103919824A CN103919824A CN201410192332.4A CN201410192332A CN103919824A CN 103919824 A CN103919824 A CN 103919824A CN 201410192332 A CN201410192332 A CN 201410192332A CN 103919824 A CN103919824 A CN 103919824A
- Authority
- CN
- China
- Prior art keywords
- extract
- nudicaule
- chrysasplenium nudicaule
- chrysasplenium
- acetone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of plant extract, and relates to the extract of Chrysasplenium nudicaule with a lipid-lowering effect. The extract is prepared through the following steps that (1) Chrysasplenium nudicaule is smashed and put into an oven to be dried, 70%-90% of acetone is added, water bathed reflux extraction is carried out, and the acetone is recycled from an extracting solution, and total extractive extract of the Chrysasplenium nudicaule is obtained; (2) stirring dissolution and filtration are carried out on the obtained total extractive extract of the Chrysasplenium nudicaule in a mixed solution with the ratio of chloroform and methyl alcohol of 50 : 1 under the condition of water bath, and chromatographic separation is carried out on filter liquor after vacuum concentration is carried out in water bath; (3) column chromatography isolation is carried out by selecting AB-8 type macroreticular resin, the diameter height ratio of resin columns is 1 : 7-9, the sample volume is 6 BV -8 BV, edulcoration is carried out by washing 4 BV -6 BV, elution is carried out by adopting eluent 7 BV - 9 BV with the ratio of ethyl acetate and acetone of 100 : 1, the flow speed is 2 BV/ h -4BV/h, the eluent is collected, and the lipid-lowering plant extract can be obtained through concentration and drying of the eluent.
Description
Technical field
The invention belongs to plant extract field, relate to a kind of Chrysasplenium nudicaule extract with effect for reducing blood fat.
Background technology
Blood fat is the general name of contained lipid in human plasma, comprising cholesterol, triglyceride, cholesterol ester, beta lipoprotein, phospholipid, not esterified fat acid etc.When serum cholesterol exceedes 230 milligrams/100 milliliters of normal values, triglyceride exceedes 140 milligrams/100 milliliters, beta lipoprotein exceed 390 milligrams/when more than 100 milliliters, can be referred to as hyperlipidemia.
The cause of disease of hyperlipidemia:
(1) Primary hyperlipemia, is exactly originally without any other disease, hyperlipemia to occur, and is generally because inherited genetic factors.
(2) Secondary Hyperlipidemia, the hyperlipemia causing due to a variety of causes exactly, such as diabetes, hypothyroidism, nephrotic syndrome, renal transplantation, biliary obstruction etc.
(3) Bad Eating Habit hyperlipemia together, as eating and drinking too much at one meal, be addicted to drink, monophagia, diet are irregular etc.
(4) certain drug induced hyperlipemia of long-term taking, as contraceptive, hormone medicine etc.
(5) hyperlipemia that Nervous and Mental Factors causes, is exactly due to long-term psychentonia, causes endocrine and metabolic disorders, forms year in and year out hyperlipemia.
The mode of prevention hyperlipemia:
(1) reasonable diet: reduce the absorption level of metabolism of lipid and cholesterol, control body weight, prevent or correct obesity, diuresis row sodium, regulates blood volume, the protection heart, brain, kidney vascular system function.Adopt low fat low cholesterol, low sodium, homovitamin, appropriate protein and energy diet.
(2) select suitable sports events: according to s own situation, select rational sports events.
(3) grasp exercise intensity: exercise heart rate is 60～70% of my maximum heart rate, is approximately equivalent to 50～60% maximal oxygen uptake.Within general 40 years old, Rate control is at 140 beats/min; 50 years old 130 beats/min; More than 60 years old be advisable with interior for 120 beats/min.
(4) suitable motion frequency: middle-aged and elderly people, particularly old people are because organism metabolism level reduces, and fatigue is the time lengthening of recovery afterwards, and therefore motion frequency can optionally increase and decrease, and is generally advisable for 3～4 times weekly.
(5) suitable movement time: each movement time is controlled at 30～40 minutes, afternoon, motion was best, and should adhere to motion exercise all the year round.
Chrysasplenium nudicaule, source: Saxifragaceae Chrysasplenium nudicaule Chrysosplenium nudicaule Bunge, with all herbal medicine.Perennial herb is high 4.5～10 centimetres.Stem is dredged raw brown pubescence or nipple projection, conventionally without leaf.Basal leaf tool long handle, blade keratin, kidney shape, is about 9 millimeters, wide approximately 13 millimeters, (tooth oblateness, is about 3 millimeters to the shallow tooth of edge tool, wide approximately 4 millimeters, first concave end and tool 1 wart point, conventionally folded knot mutually), two sides is without hair, between cog sinus place tool brown pubescence or nipple projection; Long 1～7.5 centimetre of petiole, raw brown pubescence is dredged in bottom.Distributed areas: Qinghai, Gansu, Yunnan, Xinjiang, Tibet.Nature and flavor: micro-hardship, cold.Function cures mainly: function of gallbladder promoting, preventing or arresting vomiting.Treatment jaundice and multiple gallbladder disease, tell yellow fluid.
The invention provides a kind of Chrysasplenium nudicaule extract for the treatment of hyperlipidemia, studies have shown that this extract has obvious effect for reducing blood fat.
Summary of the invention
The object of this invention is to provide a kind of Chrysasplenium nudicaule extract.
Another object of the present invention is to provide the preparation method of this extract.
This extract that also provides of the present invention is treated the application in hyperlipidemia and vascular hypertension medicine in preparation.
The object of the invention is to realize in the following manner:
Have a Chrysasplenium nudicaule extract for effect for reducing blood fat, this Chrysasplenium nudicaule extract is adopted preparation with the following method:
(1) Chrysasplenium nudicaule is pulverized, put interior 40 DEG C～50 DEG C of baking oven and dry after 3h～5h, add 15～25 times of amount 70%～90% acetone, in 60 DEG C～70 DEG C water-bath reflux, extract, 2 times～4 times, each 70min～80min, merge extractive liquid,, reclaim acetone, obtain Chrysasplenium nudicaule total extract extractum;
(2) the mixed solution stirring and dissolving under 40 DEG C～50 DEG C water bath condition with chloroform: methanol=50:1 by the Chrysasplenium nudicaule total extract extractum obtaining, filters, and filtrate is carried out chromatography after concentrating under reduced pressure in 40 DEG C～50 DEG C water-baths;
(3) select AB-8 type macroporous adsorbent resin to carry out column chromatography for separation, resin column blade diameter length ratio is 1:7～9, loading volume 6BV～8BV, washing 4BV～6BV remove impurity, with eluant 7BV～9BV eluting of ethyl acetate: acetone=100:1, flow velocity is 2BV/h～4BV/h, collect eluent, eluent is concentrated, dry, to obtain final product.
Described Chrysasplenium nudicaule extract is preferably adopted preparation with the following method:
(1) Chrysasplenium nudicaule is pulverized, put in baking oven 40 DEG C and dry after 5h, add 15 times of amount 90% acetone, in 60 DEG C of water-bath reflux, extract, 4 times, each 70min, merge extractive liquid,, reclaims acetone, obtains Chrysasplenium nudicaule total extract extractum;
(2) the mixed solution stirring and dissolving under 50 DEG C of water bath condition with chloroform: methanol=50:1 by the Chrysasplenium nudicaule total extract extractum obtaining, filters, and filtrate is carried out chromatography after concentrating under reduced pressure in 50 DEG C of water-baths;
(3) select AB-8 type macroporous adsorbent resin to carry out column chromatography for separation, resin column blade diameter length ratio is 1:7, loading volume 8BV, washing 4BV remove impurity, with the eluant 9BV eluting of ethyl acetate: acetone=100:1, flow velocity is 2BV/h, collects eluent, eluent is concentrated, dry, to obtain final product.
Described Chrysasplenium nudicaule extract can also preferably be adopted preparation with the following method:
(1) Chrysasplenium nudicaule is pulverized, put in baking oven 50 DEG C and dry after 3h, add 25 times of amount 70% acetone, in 70 DEG C of water-bath reflux, extract, 2 times, each 80min, merge extractive liquid,, reclaims acetone, obtains Chrysasplenium nudicaule total extract extractum;
(2) the mixed solution stirring and dissolving under 40 DEG C of water bath condition with chloroform: methanol=50:1 by the Chrysasplenium nudicaule total extract extractum obtaining, filters, and filtrate is carried out chromatography after concentrating under reduced pressure in 40 DEG C of water-baths;
(3) select AB-8 type macroporous adsorbent resin to carry out column chromatography for separation, resin column blade diameter length ratio is 1:9, loading volume 6BV, washing 6BV remove impurity, with the eluant 7BV eluting of ethyl acetate: acetone=100:1, flow velocity is 4BV/h, collects eluent, eluent is concentrated, dry, to obtain final product.
Described Chrysasplenium nudicaule extract can also preferably be adopted preparation with the following method:
(1) Chrysasplenium nudicaule is pulverized, put in baking oven 45 DEG C and dry after 4h, add 20 times of amount 80% acetone, in 65 DEG C of water-bath reflux, extract, 3 times, each 75min, merge extractive liquid,, reclaims acetone, obtains Chrysasplenium nudicaule total extract extractum;
(2) the mixed solution stirring and dissolving under 45 DEG C of water bath condition with chloroform: methanol=50:1 by the Chrysasplenium nudicaule total extract extractum obtaining, filters, and filtrate is carried out chromatography after concentrating under reduced pressure in 45 DEG C of water-baths;
(3) select AB-8 type macroporous adsorbent resin to carry out column chromatography for separation, resin column blade diameter length ratio is 1:8, loading volume 7BV, washing 5BV remove impurity, with the eluant 8BV eluting of ethyl acetate: acetone=100:1, flow velocity is 3BV/h, collects eluent, eluent is concentrated, dry, to obtain final product.
Described Chrysasplenium nudicaule extract, is characterized in that, this Chrysasplenium nudicaule extract adopts pharmaceutical methods conventional in pharmacy to be prepared into oral formulations.
Described oral formulations is preferably prepared as tablet, pill, hard capsule, granule, oral liquid.
Described Chrysasplenium nudicaule extract can be prepared as follows as hard capsule: get Chrysasplenium nudicaule extract, be ground into fine powder, add adjuvant, mix, pack hard capsule into, to obtain final product.
Described Chrysasplenium nudicaule extract can be prepared as follows as tablet: gets Chrysasplenium nudicaule extract, is ground into fine powder, add adjuvant, mix, and granulation, dry, compacting in flakes, to obtain final product.
Chrysasplenium nudicaule extract of the present invention is used in preparation treatment hyperlipidemia medicine or health product.
Chrysasplenium nudicaule extract of the present invention is also used in preparation treatment vascular hypertension medicine or health product.
Verify technique effect of the present invention by following experimentation:
Experiment one: the experimentation of Chrysasplenium nudicaule extract effect for reducing blood fat
1 experiment material
1.1 medicine Chrysasplenium nudicaule extracts (according to the method preparation described in description embodiment 1 of the present invention); XUEZHIKANG JIAONANG (Beijing WBL Peking University Biotech Co., Ltd).
1.2 reagent triglyceride determination test kits, T-CHOL is measured test kit, low-density LP determination reagent box, high-density LP determination reagent box.
1.3 animal Kunming mouses, male and female half and half, body weight 18～22g.
1.4 instrument B-260 type thermostat water baths, TDL80-2B type low speed centrifuge, DG5033A type enzyme-linked immunosorbent assay instrument.
2 experimental techniques
The preparation of 2.1 test samples
2.1.1 the medicinal liquid of high dose group is prepared precision and is taken Chrysasplenium nudicaule extract sample 3g, and adding 100mL concentration is 0.5%CMC-Na, is mixed with the medicinal liquid that concentration is 0.03g/mL, for subsequent use.
2.1.2 the medicinal liquid of low dose group is prepared precision and is taken Chrysasplenium nudicaule extract sample 1.5g, and the same method, is mixed with the medicinal liquid that concentration is 0.015g/mL, for subsequent use.
2.1.3 the medicinal liquid of positive controls is prepared precision and is taken Xuezhikang content 5g, and the same method, is mixed with the medicinal liquid that concentration is 0.05g/mL, for subsequent use.
Egg yolk liquid 75mL is drawn in the preparation of 2.2 egg-nog solution, puts in the graduated cylinder of 100mL, to 100mL, is made into 75% egg-nog homogeneous solution with normal saline dilution.
2.3 groupings are got 50 Kunming mouses with administration, male and female half and half, body weight is within the scope of 18～22g, be divided at random 5 groups, every group 10, be respectively: Normal group, hyperlipidemia model group, positive controls, high dose Chrysasplenium nudicaule extract administration group and low dosage Chrysasplenium nudicaule extract administration group, gastric infusion.It is 0.5%CMC-Na solution that Normal group and hyperlipidemia model group give concentration every day, and giving volume is 0.2mL/10g; Positive controls, Chrysasplenium nudicaule extract high dose administration group, Chrysasplenium nudicaule extract low dosage administration group gives respectively relative medicine, and dosage is respectively 1g/kg, 0.6g/kg and 0.3g/kg.Administration 14 days, last two hours after administration, except Normal group, all the other respectively organize equal lumbar injection 75% egg-nog solution 0.02mL/g modeling, modeling, after 20 hours, is got blood from eyeball, by blood sample in 3000rpmmin
-1centrifugal 10min, separation obtains serum, according to T-CHOL, triglyceride, low density lipoprotein, LDL and the operation of high density lipoprotein test kit description, measures the concentration of T-CHOL (TC), triglyceride (TG), low density lipoprotein, LDL (LDL-C) and high density lipoprotein (HDL-C).
2.4 statistical procedures the data obtaineds carry out statistical analysis with SPSS10.0 statistical software, analysis result with
± s represents there is statistical significance with P<0.05.
3 experimental results
The administration of various dose Chrysasplenium nudicaule extract is after 14 days, measure respectively the concentration of each group of T-CHOL (TC), triglyceride (TG), low density lipoprotein, LDL (LDL-C) and the high density lipoprotein (HDL-C) in experiment mice serum, experiment and analysis result are in table 1.
The impact of table 1 various dose Chrysasplenium nudicaule extract administration group on the corresponding blood lipids index of mice (
± s)
Note: with Normal group comparison, ##P<0.01; With the comparison of hyperlipidemia model group, * * P<0.01, * P<0.05
Experimental result shows, TC, the TG of hyperlipidemia model group, the water average specific Normal group of LDL-C significantly raise (P<0.01), the level of HDL-C decreases (P<0.01) than Normal group, shows induced Hyperlipidemia in Mice model modeling success; Compared with model group, Chrysasplenium nudicaule extract high and low dose administration group all can significantly reduce TC, TG, the LDL-C level (P<0.01) of mice, can the raise level (P<0.05) of HDL-C, and effect of high dosage is more obvious.
4 conclusions
This experimentation shows that Chrysasplenium nudicaule extract has obvious effect to the reduction of TC, TG, LDL-C, HDL-C is had to obvious rising effect, Chrysasplenium nudicaule extract has the definite effect that reduces laboratory animal blood fat, and it has the prospect that is developed as blood lipid-lowering medicine.
Study and also show, Chrysasplenium nudicaule extract of the present invention also has good hypotensive effect, can treat vascular hypertension.
detailed description of the invention:
embodiment 1:
(1) Chrysasplenium nudicaule is pulverized to 20kg, put in baking oven 45 DEG C and dry after 4h, add 20 times of amount 80% acetone, in 65 DEG C of water-bath reflux, extract, 3 times, each 75min, merge extractive liquid,, reclaims acetone, obtains Chrysasplenium nudicaule total extract extractum;
(2) the mixed solution stirring and dissolving under 45 DEG C of water bath condition with chloroform: methanol=50:1 by the Chrysasplenium nudicaule total extract extractum obtaining, filters, and filtrate is carried out chromatography after concentrating under reduced pressure in 45 DEG C of water-baths;
(3) select AB-8 type macroporous adsorbent resin to carry out column chromatography for separation, resin column blade diameter length ratio is 1:8, loading volume 7BV, washing 5BV remove impurity, with the eluant 8BV eluting of ethyl acetate: acetone=100:1, flow velocity is 3BV/h, collect eluent, eluent is concentrated, dry, obtains Chrysasplenium nudicaule extract 10.4g.
embodiment 2:
(1) Chrysasplenium nudicaule is pulverized to 20kg, put in baking oven 40 DEG C and dry after 5h, add 15 times of amount 90% acetone, in 60 DEG C of water-bath reflux, extract, 4 times, each 70min, merge extractive liquid,, reclaims acetone, obtains Chrysasplenium nudicaule total extract extractum;
(2) the mixed solution stirring and dissolving under 50 DEG C of water bath condition with chloroform: methanol=50:1 by the Chrysasplenium nudicaule total extract extractum obtaining, filters, and filtrate is carried out chromatography after concentrating under reduced pressure in 50 DEG C of water-baths;
(3) select AB-8 type macroporous adsorbent resin to carry out column chromatography for separation, resin column blade diameter length ratio is 1:7, loading volume 8BV, washing 4BV remove impurity, with the eluant 9BV eluting of ethyl acetate: acetone=100:1, flow velocity is 2BV/h, collect eluent, eluent is concentrated, dry, obtains Chrysasplenium nudicaule extract 10.2g.
embodiment 3:
(1) Chrysasplenium nudicaule is pulverized to 20kg, put in baking oven 50 DEG C and dry after 3h, add 25 times of amount 70% acetone, in 70 DEG C of water-bath reflux, extract, 2 times, each 80min, merge extractive liquid,, reclaims acetone, obtains Chrysasplenium nudicaule total extract extractum;
(2) the mixed solution stirring and dissolving under 40 DEG C of water bath condition with chloroform: methanol=50:1 by the Chrysasplenium nudicaule total extract extractum obtaining, filters, and filtrate is carried out chromatography after concentrating under reduced pressure in 40 DEG C of water-baths;
(3) select AB-8 type macroporous adsorbent resin to carry out column chromatography for separation, resin column blade diameter length ratio is 1:9, loading volume 6BV, washing 6BV remove impurity, with the eluant 7BV eluting of ethyl acetate: acetone=100:1, flow velocity is 4BV/h, collect eluent, eluent is concentrated, dry, obtains Chrysasplenium nudicaule extract 9.8g.
embodiment 4: tablet
Get Chrysasplenium nudicaule extract, add appropriate amount of starch, mix, granulation, dry, in flakes, coating, to obtain final product in compacting.
embodiment 5: tablet
Get Chrysasplenium nudicaule extract, add appropriate dextrin, mix, tabletting, to obtain final product.
embodiment 6: hard capsule
Get Chrysasplenium nudicaule extract, add appropriate dextrin, mix, granulation, incapsulates, and makes hard capsule, to obtain final product.
Claims (10)
1. a Chrysasplenium nudicaule extract with effect for reducing blood fat, is characterized in that, this Chrysasplenium nudicaule extract is adopted preparation with the following method:
(1) Chrysasplenium nudicaule is pulverized, put interior 40 DEG C～50 DEG C of baking oven and dry after 3h～5h, add 15～25 times of amount 70%～90% acetone, in 60 DEG C～70 DEG C water-bath reflux, extract, 2 times～4 times, each 70min～80min, merge extractive liquid,, reclaim acetone, obtain Chrysasplenium nudicaule total extract extractum;
(2) the mixed solution stirring and dissolving under 40 DEG C～50 DEG C water bath condition with chloroform: methanol=50:1 by the Chrysasplenium nudicaule total extract extractum obtaining, filters, and filtrate is carried out chromatography after concentrating under reduced pressure in 40 DEG C～50 DEG C water-baths;
(3) select AB-8 type macroporous adsorbent resin to carry out column chromatography for separation, resin column blade diameter length ratio is 1:7～9, loading volume 6BV～8BV, washing 4BV～6BV remove impurity, with eluant 7BV～9BV eluting of ethyl acetate: acetone=100:1, flow velocity is 2BV/h～4BV/h, collect eluent, eluent is concentrated, dry, to obtain final product.
2. Chrysasplenium nudicaule extract as claimed in claim 1, is characterized in that, this Chrysasplenium nudicaule extract is adopted preparation with the following method:
(1) Chrysasplenium nudicaule is pulverized, put in baking oven 40 DEG C and dry after 5h, add 15 times of amount 90% acetone, in 60 DEG C of water-bath reflux, extract, 4 times, each 70min, merge extractive liquid,, reclaims acetone, obtains Chrysasplenium nudicaule total extract extractum;
(2) the mixed solution stirring and dissolving under 50 DEG C of water bath condition with chloroform: methanol=50:1 by the Chrysasplenium nudicaule total extract extractum obtaining, filters, and filtrate is carried out chromatography after concentrating under reduced pressure in 50 DEG C of water-baths;
(3) select AB-8 type macroporous adsorbent resin to carry out column chromatography for separation, resin column blade diameter length ratio is 1:7, loading volume 8BV, washing 4BV remove impurity, with the eluant 9BV eluting of ethyl acetate: acetone=100:1, flow velocity is 2BV/h, collects eluent, eluent is concentrated, dry, to obtain final product.
3. Chrysasplenium nudicaule extract as claimed in claim 1, is characterized in that, this Chrysasplenium nudicaule extract is adopted preparation with the following method:
(1) Chrysasplenium nudicaule is pulverized, put in baking oven 50 DEG C and dry after 3h, add 25 times of amount 70% acetone, in 70 DEG C of water-bath reflux, extract, 2 times, each 80min, merge extractive liquid,, reclaims acetone, obtains Chrysasplenium nudicaule total extract extractum;
(2) the mixed solution stirring and dissolving under 40 DEG C of water bath condition with chloroform: methanol=50:1 by the Chrysasplenium nudicaule total extract extractum obtaining, filters, and filtrate is carried out chromatography after concentrating under reduced pressure in 40 DEG C of water-baths;
(3) select AB-8 type macroporous adsorbent resin to carry out column chromatography for separation, resin column blade diameter length ratio is 1:9, loading volume 6BV, washing 6BV remove impurity, with the eluant 7BV eluting of ethyl acetate: acetone=100:1, flow velocity is 4BV/h, collects eluent, eluent is concentrated, dry, to obtain final product.
4. Chrysasplenium nudicaule extract as claimed in claim 1, is characterized in that, this Chrysasplenium nudicaule extract is adopted preparation with the following method:
(1) Chrysasplenium nudicaule is pulverized, put in baking oven 45 DEG C and dry after 4h, add 20 times of amount 80% acetone, in 65 DEG C of water-bath reflux, extract, 3 times, each 75min, merge extractive liquid,, reclaims acetone, obtains Chrysasplenium nudicaule total extract extractum;
(2) the mixed solution stirring and dissolving under 45 DEG C of water bath condition with chloroform: methanol=50:1 by the Chrysasplenium nudicaule total extract extractum obtaining, filters, and filtrate is carried out chromatography after concentrating under reduced pressure in 45 DEG C of water-baths;
(3) select AB-8 type macroporous adsorbent resin to carry out column chromatography for separation, resin column blade diameter length ratio is 1:8, loading volume 7BV, washing 5BV remove impurity, with the eluant 8BV eluting of ethyl acetate: acetone=100:1, flow velocity is 3BV/h, collects eluent, eluent is concentrated, dry, to obtain final product.
5. the Chrysasplenium nudicaule extract as described in claim 1～4 any one, is characterized in that, this Chrysasplenium nudicaule extract adopts pharmaceutical methods conventional in pharmacy to be prepared into oral formulations.
6. Chrysasplenium nudicaule extract as claimed in claim 5, is characterized in that, this Chrysasplenium nudicaule extract adopts pharmaceutical methods conventional in pharmacy to be prepared into tablet, pill, hard capsule, granule, oral liquid.
7. Chrysasplenium nudicaule extract as claimed in claim 6, is characterized in that, this Chrysasplenium nudicaule extract is adopted preparation with the following method: get Chrysasplenium nudicaule extract, be ground into fine powder, add adjuvant, mix, pack hard capsule into, to obtain final product.
8. Chrysasplenium nudicaule extract as claimed in claim 6, is characterized in that, this Chrysasplenium nudicaule extract is adopted preparation with the following method: get Chrysasplenium nudicaule extract, be ground into fine powder, add adjuvant, mix, and granulation, dry, compacting in flakes, to obtain final product.
9. the Chrysasplenium nudicaule extract as described in claim 1～4 any one, is characterized in that, the application of this Chrysasplenium nudicaule extract in preparation treatment hyperlipidemia medicine or health product.
10. the Chrysasplenium nudicaule extract as described in claim 1～4 any one, is characterized in that, the application of this Chrysasplenium nudicaule extract in preparation treatment vascular hypertension medicine or health product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410192332.4A CN103919824B (en) | 2014-05-08 | 2014-05-08 | The plant extract of a kind of blood fat reducing and the application in preparing medicine or health product thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410192332.4A CN103919824B (en) | 2014-05-08 | 2014-05-08 | The plant extract of a kind of blood fat reducing and the application in preparing medicine or health product thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103919824A true CN103919824A (en) | 2014-07-16 |
| CN103919824B CN103919824B (en) | 2016-06-29 |
Family
ID=51138366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410192332.4A Expired - Fee Related CN103919824B (en) | 2014-05-08 | 2014-05-08 | The plant extract of a kind of blood fat reducing and the application in preparing medicine or health product thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103919824B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103585206A (en) * | 2013-10-31 | 2014-02-19 | 济南星懿医药技术有限公司 | Preparation method of Chrysosplenium extract and its application |
| CN103585205A (en) * | 2013-10-31 | 2014-02-19 | 济南星懿医药技术有限公司 | Application of Chrysosplenium extract in preparation of drugs treating diabetes |
-
2014
- 2014-05-08 CN CN201410192332.4A patent/CN103919824B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103585206A (en) * | 2013-10-31 | 2014-02-19 | 济南星懿医药技术有限公司 | Preparation method of Chrysosplenium extract and its application |
| CN103585205A (en) * | 2013-10-31 | 2014-02-19 | 济南星懿医药技术有限公司 | Application of Chrysosplenium extract in preparation of drugs treating diabetes |
Non-Patent Citations (1)
| Title |
|---|
| 王玉平等: "藏药金腰草中黄酮诱导K562细胞凋亡及其分子机制研究", 《实用癌症杂志》, vol. 20, no. 4, 31 July 2005 (2005-07-31), pages 374 - 376 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103919824B (en) | 2016-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104435226B (en) | Fevervine extract and application thereof | |
| CN102836188A (en) | Folium microcotis total flavone extract and preparation method and application thereof | |
| CN103169788B (en) | Chinese date leaf extractive and application thereof in preparation of medicament or health food for preventing and treating liver injury | |
| CN101618096B (en) | Madder extract and preparation method and application thereof | |
| CN102224924B (en) | Sea cucumber saponin-containing composition and its application in foods and drugs | |
| CN104013636A (en) | Anti-tumor pharmaceutical use of pentacyclic triterpene saponin compounds of szechuan melandium root | |
| CN113730464A (en) | New application of rhizoma coptidis pill, extract and pharmaceutical composition thereof and rhizoma coptidis pill product | |
| CN106535912B (en) | Control pharmaceutical composition and its application of human body blood fat and body weight | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN103893412B (en) | A kind of antitumor beautyberry extract and its production and use | |
| CN103405494A (en) | Bauhinia championii n-butyl alcohol extract and preparation method and application thereof | |
| CN105106300A (en) | Use of cyclocarya paliurus extract in preparation of drug for preventing and treating non-alcoholic fatty liver disease | |
| CN109674848A (en) | A kind of preparation method and purposes of licorice | |
| CN106138164A (en) | A kind of compound Chinese medicinal preparation with Adjust-blood lipid function | |
| CN105535152B (en) | Application of loquat leaf total sesquiterpene extract | |
| CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
| CN103919824B (en) | The plant extract of a kind of blood fat reducing and the application in preparing medicine or health product thereof | |
| CN106619777A (en) | Traditional Chinese medicine composition containing honeysuckle stems and leaves for preventing and treating constipation, preparation method and application | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN107252440A (en) | A kind of preparation method and purposes of the Hickory Leaves general flavone with hypoglycemic effect | |
| CN103877513A (en) | Chinese herbal compound composition with blood fat reduction effect, and applications thereof | |
| CN104127486B (en) | Application of the Radix Lamiophlomidis Rotatae total iridoid glycosides extract in treatment constipation medicine is prepared | |
| CN114515009B (en) | Composition with weight-losing and lipid-lowering effects and application thereof | |
| CN109223739A (en) | A kind of composition and its preparation method and application | |
| CN112089783B (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing or/and treating obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| CB03 | Change of inventor or designer information |
Inventor after: Meng Xin Inventor after: Liu Weili Inventor after: Tian Yuan Inventor after: Sun Yanan Inventor before: Li Yang Inventor before: Yao Lin Inventor before: Wu Pingan |
|
| COR | Change of bibliographic data | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160524 Address after: 150040 Heping Road, Xiangfang District, Heilongjiang, Harbin, China, 24 Applicant after: Heilongjiang University of Chinese Medicine Address before: 222001 Jiangsu Province, Lianyungang city Sinpo District Road Gui Juyuan Yingzhou District 16 Building 1 floor A5 No. 06 Lianyungang Zhiyuan pharmaceutical facade Technology Services Ltd. Applicant before: Wang Hengxin |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160629 Termination date: 20170508 |